Developing a new treatment for Canavan Disease using NAT8L inhibitors
Development of NAT8L inhibitors for the Treatment of Canavan Disease
This study is looking at a new treatment for Canavan Disease, a condition that affects how children's brains develop, and aims to create a medicine that can help reduce harmful substances in the brain to improve their thinking and movement skills.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10872391 on NIH RePORTER |
What this research studies
This research focuses on Canavan Disease, a genetic disorder that affects brain development and function in children. The team is working to develop NAT8L inhibitors that can penetrate the blood-brain barrier and reduce harmful levels of N-acetylaspartate (NAA) in the brain, which are responsible for the disease's symptoms. By optimizing a promising compound identified through high-throughput screening, the researchers aim to create an effective therapy that could improve cognitive and motor functions in affected patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are children under 11 years old diagnosed with Canavan Disease.
Not a fit: Patients with other neurological disorders or those over the age of 11 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that alleviates the symptoms of Canavan Disease and improves the quality of life for patients.
How similar studies have performed: Previous research has shown promising results in animal models using similar approaches, indicating potential for success in human applications.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Tsukamoto, Takashi — Johns Hopkins University
- Study coordinator: Tsukamoto, Takashi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.